Japanese pharma company Daiichi Sankyo will close two of its subsidiary R&D facilities in Gurgaon, India, and Kobe, Japan.

Around 150 employees at Asubio Pharma in Kobe focus mainly on psychiatric and neurological diseases, immune and inflammatory diseases and regenerative medicine. Daiichi expects to transfer these projects and employees to its other sites in Japan.

Daiichi Sankyo India Pharma focuses on infectious diseases and inflammation. After the closure, which will affect around 170 employees, the projects will transfer to Daiichi’s central R&D division.